Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Lilit Kazangyan

Lilit Kazangyan

Special Counsel
Los Angeles +1 424 332 4769 lkazangyan@cov.com Download V-card

Lilit Kazangyan represents investment banks as well as public and private companies in connection with a variety of domestic and international capital markets transactions, including initial public offerings, follow-on offerings, and high-yield and investment grade debt offerings. Ms. Kazangyan has significant experience in capital market financings by special purpose acquisition companies (SPACs). She also advises clients on general corporate matters, including securities laws compliance and corporate governance.

  • Represented the underwriters in the initial public offering and subsequent follow-on offering of NeuroDerm Ltd., an Israel-based clinical-stage biopharmaceutical company focused on treatments for central nervous system disorders.
  • Represented the underwriters in the initial public offering and subsequent follow-on offering of Affimed N.V., a German-based clinical-stage biotechnology company focused on cancer immunotherapies.
  • Represented the underwriters in the initial public offering and subsequent follow-on offering of uniQure N.V., a Netherlands-based biotechnology company focused on gene therapies.
  • Represented the underwriters in several public offerings of debt and equity for Senior Housing Properties Trust, a real estate investment trust that invests in senior living properties.
  • Represented the underwriter in the initial public offering of Presbia PLC, an Ireland-based ophthalmic device company marketing an optical lens implant for treating presbyopia.
  • Represented the underwriters in the initial public offering of OncoMed Pharmaceuticals, Inc., a U.S.-based clinical-stage biopharmaceutical company developing antibody therapeutics targeting cancer stem cells.
  • Represented the underwriters in several follow-on equity offerings for Celldex Therapeutics, Inc., a biopharmaceutical company focused on cancer immunotherapies.
  • Represented the underwriters in several follow-on equity offerings for Exact Sciences Corporation, a molecular diagnostics company focused on early detection of colorectal cancer.